This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arvinas, Inc. (ARVN) and ImmunoGen (IMGN) have performed compared to their sector so far this year.
Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 42.1% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arvinas, Inc. (ARVN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
by Zacks Equity Research
Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.
Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 145.5% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Arvinas, Inc. (ARVN) points to a 165.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Arvinas, Inc. (ARVN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.
Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat
by Zacks Equity Research
Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise.
Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength?
by Zacks Equity Research
Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of 25.15% and 67.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -5.48% and 5.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 9.09% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -50% and 8.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Arvinas, Inc. (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arvinas, Inc. (ARVN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.53% and 31.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Why Arvinas (ARVN) Might Surprise This Earnings Season
by Zacks Equity Research
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Strength Seen in Arvinas, Inc. (ARVN): Can Its 12% Jump Turn into More Strength?
by Zacks Equity Research
Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?